ASRT vs REGN · rev $125.0M vs P/E 14, rev $14.34B
Assertio Therapeutics Inc (ASRT) versus Regeneron Pharmaceuticals Inc (REGN) — a side-by-side from cached financials, not a winner call.
Assertio Therapeutics Inc (ASRT) is a drug manufacturers - specialty & generic company listed on US.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Latest reported ASRT revenue for 2024-12-31 was $125.0M. Net income was -$21.6M. Revenue was down 17.8% from 2023-12-31 to 2024-12-31. ASRT currently screens at market cap $151.5M.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
ASRT currently screens at market cap $151.5M. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Not investment advice. Open the ASRT and REGN stock pages for the full models.
Not investment advice.